Aurinia Pharmaceuticals Inc (AUPH)vsEli Lilly and Company (LLY)
AUPH
Aurinia Pharmaceuticals Inc
$16.21
0.00%
HEALTHCARE · Cap: $2.17B
LLY
Eli Lilly and Company
$1,430.13
-0.70%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 26773% more annual revenue ($86.46B vs $321.74M). AUPH leads profitability with a 97.7% profit margin vs 31.9%. AUPH trades at a lower P/E of 7.1x. LLY earns a higher WallStSmart Score of 74/100 (B).
AUPH
Buy59
out of 100
Grade: C
LLY
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 98 of every $100 in revenue as profit
Strong operational efficiency at 51.6%
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 97.7% and operating margin at 51.6%. Revenue growth of 13.9% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : AUPH
The primary concerns for AUPH are EPS Growth.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
AUPH profiles as a mature stock while LLY is a growth play — different risk/reward profiles.
AUPH carries more volatility with a beta of 1.34 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 59/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?